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Background: Recent genome-wide analysis has shown that DNA methylation spans long stretches of chromosome
regions consisting of clusters of contiguous CpG islands or gene families. Hypermethylation of various gene clusters
has been reported in many types of cancer. In this study, we conducted methyl-binding domain capture (MBDCap)
sequencing (MBD-seq) analysis on a breast cancer cohort consisting of 77 patients and 10 normal controls, as well
as a panel of 38 breast cancer cell lines.
Results: Bioinformatics analysis determined seven gene clusters with a significant difference in overall survival (OS)
and further revealed a distinct feature that the conservation of a large gene cluster (approximately 70 kb)
metallothionein-1 (MT1) among 45 species is much lower than the average of all RefSeq genes. Furthermore, we
found that DNA methylation is an important epigenetic regulator contributing to gene repression of MT1 gene
cluster in both ERα positive (ERα+) and ERα negative (ERα−) breast tumors. In silico analysis revealed much lower
gene expression of this cluster in The Cancer Genome Atlas (TCGA) cohort for ERα + tumors. To further investigate
the role of estrogen, we conducted 17β-estradiol (E2) and demethylating agent 5-aza-2′-deoxycytidine (DAC)
treatment in various breast cancer cell types. Cell proliferation and invasion assays suggested MT1F and MT1M may
play an anti-oncogenic role in breast cancer.
Conclusions: Our data suggests that DNA methylation in large contiguous gene clusters can be potential
prognostic markers of breast cancer. Further investigation of these clusters revealed that estrogen mediates
epigenetic repression of MT1 cluster in ERα + breast cancer cell lines. In all, our studies identify thousands of breast
tumor hypermethylated regions for the first time, in particular, discovering seven large contiguous hypermethylated
gene clusters.
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Aberrant epigenetic changes, including DNA methyla-
tion and histone modifications, have been known to
be the hallmark of cancer [1]. These changes usually
disrupt the regulation of many oncogenes or tumor
suppressor genes in tumors, resulting in their abnor-
mal expression. DNA methylation occurs mainly at
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unless otherwise stated.regions, where more than 60% of them are located in
5′ promoters [2]. De novo hypermethylation of these
regions, which is often associated with silencing of
many tumor suppressor genes, has been shown to play
a crucial role in the development of many types of
human cancers [3-6]. Many studies, including ours
[7-10], used a quantitative approach based on statis-
tical methods or machine learning algorithms to quan-
tify methylation differences and identify differentiallyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lation profiles in many different tissue or cancer pa-
tient cohorts. Such quantitative approaches are thus
able to provide more insights into the role of DNA
methylation in the development of various diseases
such as cancer.
Recent genome-wide analysis of DNA methylation
has revealed that this epigenetic process is not only a
site specific event but also spans long stretches of
chromosome regions consisting of clusters of contigu-
ous CpG islands [11,12] or a gene family [13-15]. Ex-
tensive hypermethylation of various gene clusters has
previously been reported. For example, hypermethyla-
tion of HOXA gene clusters was found in breast and
lung cancers [16,17], protocadherin (PCDH) in Wilms’
tumor, the region across chromosome 2q14.2 in colo-
rectal cancer and many others [18-20]. The findings in
all these studies warrant a novel gene cluster centric
approach towards the investigation of DNA methyla-
tion. In an effort to further investigate the mechanism
responsible in this long-range epigenetic silencing
(LRES), our laboratory previously elucidated the role
of estrogen in coordinate repression of these gene clus-
ters in breast cancer [21]. The study revealed that per-
sistent estrogen-mediated LRES leads to recruitment of
H3K27me3 repressive chromatin marks, which are ac-
companied by accumulation of DNA methylation in a
gene cluster located at 16p11.2.
In this study, we conducted MBDCap sequencing
(MBD-seq) analysis on a breast cancer cohort consisting
of 77 patients and 10 normal controls, as well as a panel
of 38 breast cancer cell lines. Survival analysis conducted
on 60 unique gene clusters determined seven clusters
with a significant difference in overall survival (OS) by
using methylation levels of genes in the cluster for all
patients. Bioinformatics analysis further revealed a dis-
tinct feature that the conservation of a large gene cluster
(approximately 70 kb) metallothionein-1 (MT1) among
45 species is much lower than the average of all RefSeq
genes. We also found that DNA methylation is an im-
portant factor contributing to gene repression of MT1
gene cluster regardless of the ERα status. In silico ana-
lysis using the public domain The Cancer Genome Atlas
(TCGA) data revealed that ERα positive (ERα+) breast
cancer patients show lower levels of expression for MT1
genes. To investigate if estrogen regulates repression of
MT1 cluster in ERα + breast cancer cell types, we con-
ducted 17β-estradiol (E2) and demethylating agent 5-
Aza-2′-deoxycytidine (DAC) treatment in various breast
cancer cell lines. Our data suggested that both estrogen
and DNA methylation mediate repression of the MT1
gene cluster in ERα + breast cancer cell lines. Cell prolif-
eration and invasion assays suggested MT1F and MT1M
may have anti-oncogenic roles in breast cancer.Results
MBD-seq identifies differential methylated patterns in
breast primary tumors
We conducted MBD-seq to investigate methylation pat-
terns on a genome-wide scale for a cohort of breast
cancer patients (n = 77), Integrative Cancer Biology
Program (ICBP) breast cancer cell lines (n = 38), and
normal mammary tissue (n = 10). Over 20 million unique
reads were analyzed for all samples, a coverage ex-
pected to provide sufficient sequence depth for methy-
lation mapping of the whole genome (Additional file 1:
Figure S1). Differential methylation between breast
tumor and normal control samples (Additional file 1:
Table S3) was observed in promoter CpG islands (CGIs)
(19.5% of 13,081 promoter CGIs analyzed; P < 0.05), as
well as intragenic CGIs (55.2% of 6,959 intragenic CGIs
analyzed; P < 0.01), intergenic CGIs (28.1% of 4,847 inter-
genic CGIs analyzed; P < 0.01), and non-CGI promoters
(1.8% of 5,454 non-CGI promoters; P < 0.01) (Figure 1A,
left panel). DNA hypermethylation in breast tumors
compared to normal control occurred predominantly in
CGI cores at transcription start site (TSS) regions and
also in regions flanking CGIs, or so-called CpG shores
(Figure 1A, right panel). This distinct type of methyla-
tion pattern was first reported in colon cancer [22]. Ex-
amples of loci exhibiting hypermethylation in breast
tumor samples relative to normal tissue in promoter
CGIs (CIDEA), intragenic CGIs (RASGEF1A), intergenic
CGIs (FOXB1), and non-CGI promoters (COL11A1) are
presented in Figure 1B (hypermethylated regions are
outlined by dashed squares) and in Additional file 1:
Figure S2.
Survival analysis determines significant hypermethylated
gene clusters in breast cancer
Recent studies including ours [11-13] found that DNA
methylation patterns span long stretches of chromosome
regions that mostly consist of gene clusters in different
types of cancer. We therefore examined hypermethylated
levels of more than 60 unique gene clusters in our breast
cohort (77 tumor vs. 10 normal), where hypermethyla-
tion in the breast tumors was defined in relative terms
to DNA methylation in normal breast tissue, and then
performed survival analysis to determine their signifi-
cance. Survival analysis, represented by Kaplan-Meier
curves, was conducted using the third quartile as the
cutoff value to dichotomize patients into high- and
low-methylation groups (Figure 2A). We found that
methylation levels of 38 of these unique gene clusters
were significantly correlated with OS, showing that
these gene clusters’ hypermethylated levels were a high
risk factor and positively correlated with a poor survival
(Figure 2B) (Additional file 2). We further selected seven
gene clusters from these which have been reported in the
Figure 1 DNA hypermethylation in breast cancer samples relative to normal breast tissue in promoter and non-promoter CpG islands.
Methyl capture sequencing (MBD-seq) was used to generate DNA methylation profiles of the genomes of breast tumors (n = 77) and normal breast
tissue (n = 10). (A) Pie charts demonstrate differential methylation in promoter, intragenic, and intergenic CGIs as well as non-CGI promoter regions (left
panel). Methylation of core and shore regions is also demonstrated under each corresponding CGI type (left panel). DNA hypermethylation in core and
shore regions are shown for breast tumors compared to normal tissue (right panel). (B) Example loci showing promoter CGI, intragenic, intergenic, and
non-CGI promoter regions. Dashed squares highlight regions corresponding to breast cancer hypermethylation.
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associated with estrogen interactions and/or cancer devel-
opment for further investigation [23-28]. Our analyses also
determined that most but not all of the hypermethylated
genes in a particular gene cluster were able to be includedin stratifying patients with a statistical significance, imply-
ing that these excluded few genes in the cluster may ex-
hibit a more distinct functional role. For example, 9 of 11
metallothionein-1 (MT1) genes (MT1A, B, E, G, H, L, and
X), including two hypothetical genes MT1DP and MT1IP,
Figure 2 Gene clusters hypermethylated in breast cancer and associated with poor survival. (A) Heat maps showing averaged DNA
methylation in the different gene cluster loci (left panel). (B) Kaplan-Meier survival curves indicating candidate cluster gene hypermethylation are
associated with decreased survival (right panel).
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MT1F and MT1M, which are not in the list, exert anti-
oncogenic effects (see last section in Results).
Bioinformatics analysis reveals a distinct feature of the
MT1 gene cluster
We further performed the bioinformatics analysis on
these seven gene clusters in order to gain an insight
into their underlying characterization, such as guanine-
cytosine (GC) contents and phylogenetic conservations.
As expected, the highest mean GC contents are around
5′TSS regions for all gene clusters, except PCDH gene
family, with a peak around downstream 2 kb of 5′TSS
while two gene clusters, HIST1 and PCDH, showed
lower mean GC contents than the average of all RefSeq
genes (Additional file 1: Figure S9A). Plots of phylogen-
etic conservation among 45 species (Additional file 1:
Figure S9B) showed that phastCons scores of the MT1
gene cluster are below 0.1 at 5′TSS which is lower than
the average of all RefSeq genes. Two relatively high con-
served regions (two peaks downstream 5′TSS) might be
the first exons. Our analysis is in line with a finding that
the evolution of the lineage that led to human MT1 has
undergone further duplication events that have resulted
in 13 younger duplicate isoforms [29] and the divergence
of the MT family in mammals. We also observed the
ZNF gene cluster that has relatively lower scores of 0.2
but at the same level as the average.
Next, we utilized the publicly available TCGA breast
cancer cohort, including 106 normal tissue and 988 pri-
mary tumor samples, and examined the expression values
measured by RNA-seq data for these hypermethylated
gene clusters. Interestingly, we found five gene clusters,
ZNF, PCDH, MT1, HOXD, and HOXA, which showed re-
duced expression in cancer patients compared to normal
tissues. However, the other two clusters, HOXC and
HIST1, surprisingly showed increased expression levels
(Figure 3A). Although this latter observation is inconsist-
ent with a traditional view that the promoter hypermethy-
lated genes in tumors are usually positively correlated
with lower expression, this supported a newly established
concept that the methylated status of other gene regions,
such as intragenic and 3′TTS, may also play a role in de-
termining the overall expression as demonstrated by many
studies [30-32]. Nevertheless, for the first time, our find-
ings provide a correlation between methylation status and
gene expression level at a gene cluster scale. A further de-
tailed examination of the MT1 gene cluster revealed that
the ERα + tumor samples have a much lower gene expres-
sion level than ERα negative (ERα−) tumor samples while
both display significantly lower gene expression level than
normal tissue samples (Figure 3B). However, their methy-
lation levels showed a decrease in an order of ERα +
tumor, ERα − tumor, and normal samples (Figure 3C).This positive correlation prompted us to ask if the epigen-
etic repression of this gene cluster is associated with the
status of ERα level (positive vs. negative) in the breast
tumors. To this end, we re-examined K-M survival ana-
lysis based on the status of ERα level and found that
both ERα + and ERα − patients show poor outcomes for
the hypermethylated MT1 genes (Figure 4A). A Cox pro-
portional hazard regression model further confirmed that
the hazard ratios show statistical significance for methyla-
tion, age, and grading but not for ERα status (Figure 4B).
Most of the individual genes in the cluster also showed a
significant negative correlation between DNA methylation
and gene expression in both ERα + and ERα − patient
samples (Additional file 1: Figure S10). This data sup-
ported a notion that DNA methylation is an important
factor contributing to gene repression regardless of the
estrogen receptor (ER) status in breast tumors.
Hypermethylation of the MT1 gene cluster is validated in
different breast cancer cell lines
As the hypermethylated status for the MT1 gene cluster
was observed in primary tumor samples, we further hy-
pothesized that they would also be hypermethylated in
breast cancer cell lines since these cell lines were isolated,
cultured, and homogenized from the primary tumor. In
order to confirm this hypothesis, we conducted the
MBD-seq analysis on a panel of 38 breast cancer cell
lines (Additional file 1: Figure S1). Overall, the mean
methylation level for six of the gene clusters in the cell
lines was higher than that in normal tissue samples but
lower than that in tumor samples (Additional file 1:
Figure S11). For the MT1 gene cluster, we found that
the cell line data had the highest methylation levels
followed by ERα + tumor, ERα − tumor, and normal sam-
ples (Figure 3C). A detailed visualized analysis along the
MT1 gene cluster further revealed a hypermethylation
pattern in CGIs that was associated with most MT1 TSS
sites in the breast cancer samples relative to normal breast
tissue (Figure 4C). Specifically, hypermethylation was ob-
served in promoter CGIs of MT1L, E, M, A, G, and H as
well as non-promoter CGIs M-A and F-G (Figure 4C;
hypermethylated regions are denoted by dashed squares).
The visualization of other gene clusters is shown in
Additional file 1: Figures S3-8. Taken together, our re-
sult validated the hypermethylated status of the MT1
gene cluster in many different breast cancer cell lines.
Next, we performed quantitative reverse transcription
PCR (RT-qPCR) to examine the gene expression level
for the MT1 gene cluster in selected breast cell lines, in-
cluding one normal cell line, human mammary epithelial
cells (HMEC), two ERα + cell lines, MCF7, BT474, and
two ERα − cell lines, BT20 and MDA-MB231. Although
there are publicly available gene expression data in 61
breast cancer cell lines [33], the cell lines we used for
Figure 3 Lower expression and higher methylation of MT1 gene cluster for ERα + compared to ERα − and normal patient samples is
observed in TCGA RNA-seq and our MBD-seq cohort, respectively. (A) A heat map showing RNA-seq expression data from TCGA for all the
genes in identified clusters along with fold change comparisons (left) with normal vs. tumor and ERα − vs. ERα + samples. (B) A boxplot showing
the significant difference in average gene expressions in each subset compared to normal for all the genes in MT1 gene cluster. (C) A boxplot
showing significant difference in average MT1 cluster gene methylation for each subset compared to normal samples in our MDB-seq cohort.
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with them, and some of the genes in our study were not
in the profiling. As shown in Figure 5A, overall, all genes
showed lower expression in four breast cancer cell lines
than in the HMEC cell line, except MT1F and MT1X,
where MT1F has lower in HMEC than in MCF7 and
MDA-MB231 cells, and MT1X has a similar level in
MDA-MB231 cells. Meanwhile, there are no clear differ-
ences for each individual gene in two ERα − vs. two ERα
+ breast cancer cell lines. This may be due to the cell
model not fully recapitulating the molecular characteris-
tics of the primary tumors. We also found that there are
no detectable expression levels for MT1B in all cell lines.
This is consistent with the TCGA data showing no ex-
pression for this gene in all patients and normal samples.
By examining the methylation levels in these cell lines
(Figure 5B), we found that all genes showed highermethylation in breast cancer cell lines than normal tis-
sue while we did not find a clear differential pattern be-
tween ERα + and ERα − cell lines. These validations
further support our earlier observation that the correl-
ation of lower expression with hypermethylation for this
gene cluster is independent of the status of ERα in the
breast tumors.
Estrogen mediates epigenetic repression of the MT1 gene
cluster in ERα + breast cancer cell lines
To further investigate whether estrogen mediates epi-
genetic repression of the cluster in ERα + breast cancer
cell lines, we conducted E2 and DAC treatment in vari-
ous breast cancer cell types. We first used estrogen re-
sponse element (ERE) luciferase assay to confirm that
ERE responds to E2 in ERα + cell lines, MCF7,
MDAMB134, and BT474, and not in ERα − cell lines,
Figure 4 (See legend on next page.)
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Figure 4 DNA methylation is associated with poor survival in MT1 gene cluster regardless of ERα status of patients. (A) Kaplan-Meier
survival curves indicating that MT1 gene cluster hypermethylation is associated with decreased survival in both ERα + and ERα − patients. (B) A
table showing the hazard ratios along with 95% confidence intervals and statistical significance for methylation along with other covariates. The
groups are the same as the ones used for Figure 4A and MT1 cluster in Figure 2B, that is, patients showing hypermethylation in one to nine MT1
genes in the cluster are grouped together. (C) A heat map showing methylation of MT1 gene cluster for normal breast tissue, breast tumors, and
breast cancer cell lines. Dashed-line squares highlight differentially methylated regions in these samples. Note that MT1 gene cluster consists of
nine loci (MT1L, E, M, A, B, F, G, H, and X) and two pseudogenes (MT1DP and IP) as outlined in the genomic map above the methylation profile.
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ined the differential gene expression of eight genes in
the cluster before and after the E2 and DAC treatment
(Figure 6B). We removed MT1B from this experiment
as there was no detectable expression level in the se-
lected cell lines. Surprisingly, for MCF7, a ERα + cell
line, the expression level for six genes (MT1A, F, H, M,
E, and G) significantly decreased in response to E2 or/
and DAC treatment, while no changes were observed for
two of them (MT1L and X). Similarly, MDAMB134
which is ERα + cell line but with a slightly lower EREFigure 5 Basal level expression and DNA methylation for most of the
methylation in breast cancer cell lines. (A) RT-qPCR gene expression a
representing ERα + (MCF7 and BT474) and ERα − (BT20 and MDAMB231) subs
samples for DNA methylation) revealing lower levels of expression and hactivity compared to MCF7 showed a marked decrease
in expression of five genes (MT1E, F, H, L, and X). How-
ever, for BT474, another ERα + cell line, we found that
expression levels showed no significant changes for six
genes after E2 treatment but significantly increased upon
DAC treatment for all eight genes. We also observed
that the expression levels for the combination of E2 and
DAC treatment are similar to those of E2 treatment. We
did not detect any expression changes after E2 or/and
DAC treatment in both ERα − cell lines. The distinct ex-
pression response of BT474 compared to other ERα +genes in MT1 gene cluster show lower expression and higher
nd (B) averaged methylation profiles of MT1 genes in cell lines
ets compared to normal (HMEC used for PCR and average of normal
igher levels of DNA methylation in cell lines compared to normal.
Figure 6 Differential response to E2 suppression and DAC activation of MT1 gene expression is seen in ERα + cell lines but not in
ERα − cell lines. (A) Luciferase activity of ERE reporter vector normalized to Renilla reporter activity in luminal and basal breast cancer cell lines.
(B) MT1 expression was carried out by RT-qPCR following E2 and/or DAC treatments as described in the Methods section.
Jadhav et al. Clinical Epigenetics  (2015) 7:13 Page 9 of 15cell lines may be attributed to the altered ER signal trans-
duction pathway which also contributes to its tamoxifen
resistance as reported by Wang et al. [34]. Clearly, more
experiments are needed to further explore the underlying
mechanism; our data nevertheless suggest that estrogen
plays an important role in mediating epigenetic repression
(mainly DNA hypermethylation) of the MT1 gene cluster
in ERα + breast cancer cell lines.
MT1F and MT1M expression exerts anti-oncogenic effects
in breast cancer
Since MT1 gene clusters were hypermethylated in breast
tumors from our cohort and the methylation of the genecluster was associated with poor survival, we hypothesize
that MT1 genes may play a functional role in breast
tumorigenesis. In order to test this hypothesis, we se-
lected two genes MT1F and MT1M to further investi-
gate whether knockdown of their expression can impart
a more aggressive phenotype to MCF7 cells. The MT1M
gene was selected because it is highly methylated in
ERα + cells and has been implicated as a tumor suppres-
sor in earlier studies [35], while the selection of MT1F is
because it is most highly expressed in MCF7 cells com-
pared to other cell lines (Figure 5A). In addition, both
MT1F and MT1M were highly epigenetically repressed
by E2 in MCF7 cells (Figure 6B). After sufficiently
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fected with specific siRNA for either MT1F or MT1M
(Figure 7A and Additional file 1: Table S5), we examined
the proliferation and invasion of MCF7 cells. Knock-
down of MT1F and MT1M resulted in an increased pro-
liferation in MCF7 cells compared to control siRNA
(Figure 7B). Furthermore, knockdown of MT1F and
MT1M increased the invasiveness of MCF7 cells, and
the combination knockdown had an additive invasive ef-
fect (Figure 7C,D). Taken together, we demonstrated that
MT1F and MT1M exert anti-oncogenic effects in MCF7
cells.
Discussion
Our current studies quantitatively analyzed differential
methylation patterns at a genome-wide scale on a breast
patient cohort and identified many large contiguous
hypermethylated regions mainly consisting of gene clus-
ters. Our results re-assert a newly emerging perspective
that DNA methylation goes beyond a discrete gene event
and often spans long stretches of chromosome regions.
Although this phenomenon has lately been observed
by several other studies in different types of cancer
[12-14,16,17], this study reported for the first time thatFigure 7 MT1F and MT1M knockdown leads to increased cellular pro
proliferation (A, B) and invasion (C, D) assays were carried out as describedthe tumor hypermethylation levels of a gene cluster (as
many as seven gene clusters) (Figure 2) are significantly
associated with overall survival in breast cancer patients.
More strikingly, the hypermethylation status for seven
clusters identified in the patient cohort was recapitulated
in a panel of 38 breast cancer cell lines using the same
MBD-seq protocol. Since the selection of cell lines,
which includes several sub-types of breast cancer, is
purely based on the availability at the time conducting
the experiments, our cell line data not only validate our
patient data but also further suggest that this large con-
tiguous hypermethylation across seven gene clusters
may be a distinguishing characteristic of breast cancer
and commonly exist across many different sub-types.
Our analysis of intrinsic genomic features on these
gene clusters revealed a distinct feature of the MT1 gene
cluster. Compared to other gene clusters, such as
HOXA, HOXC, HOXD, HISTI1, and ZNF, which are
highly conserved among 45 species, the conservation for
MT1 cluster is lower and even much below the average
of all RefSeq genes. Although an evolutionary study indi-
cates that the MT1 family is mammal-specific with 13
new isoforms in humans, an earlier study investigating
promoter DNA methylation has reported one of theliferation and invasion in MCF-7 cells. Knockdown as well as cellular
in the Methods section.
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progression [36]. Another study indicated that the ex-
pression of the genes in this cluster led to poor overall
survival in a subset of invasive breast cancer patients
[25]. How these genomic properties affect the biological
functions and biological processes of the genes in this
cluster, in relation with specific organs, as well as its role
in cancer development and progression, is worth further
exploration. Interestingly, our correlation analysis of the
methylation levels with the gene expression levels using
a larger TCGA breast cancer cohort data found that the
MT1 gene cluster exerts clear differential expression
patterns among ERα + tumor samples and ERα − tumor
samples (Figure 3B). Although the HOXD gene cluster
showed a similar pattern, this cluster has previously
been reported to be hypermethylated in a large cohort of
melanomas [37] as well as in astrocytomas [38], a lethal
human brain tumor, implying that it is a rather common
phenomenon for many types of cancer. So far, only this
study has reported the negative correlation of the MT1
cluster in breast cancer, that is, its gene expression levels
are decreased upon its hypermethylation, and thus, we
speculate that the hypermethylation of this cluster may
be breast cancer specific. We also observed some gene
clusters having a positive correlation, that is, their gene
expression levels were increased upon their hypermethy-
lation in breast tumors.
Despite our data supporting a notion that estrogen
mediates epigenetic repression of the MT1 gene cluster
in MCF7 cells (Figure 6), the underlying mechanism of
what triggers this long-range coordinated repression
process remains obscured. Our previous study [21] has
shown that persistent estrogen-mediated long-range re-
pression leads to recruitment of H3K27me3 repressive
chromatin marks, which are accompanied by the accu-
mulation of DNA methylation in a gene cluster located
at 16p11.2. Recent studies have also shown that estrogen
and ERα positively regulate the expression of various
methyltransferases (DNMTs), thereby contributing to
the malignant transformation of cells in various estrogen
responsive breast and endometrial cancers [39,40]. We
thus speculate that estrogen mediates the recruiting of
some chromatin modifying enzymes, such as polycomb
complex, then estrogen further recruits DNA methyla-
tion machinery, thus triggering a DNA methylation
process at a single embedded gene, which then spreads
to other neighboring genes due to their closeness and
eventually methylation of a whole cluster occurs.
One important finding in our studies is that we dem-
onstrated the invasiveness of MT1F and MT1M in
MCF7 cells (Figure 7). Despite other studies finding that
loss of MT1 or one of MT1 member genes was signifi-
cantly correlated with invasiveness in other tumor types
[41], our study depicts the anti-oncogenic role in breastcancer cell line. Our results offer mechanistic insights
into breast tumorigenesis, suggesting that methylation of
MT1 gene cluster is involved in oncogenic events. We
have used MCF7 as a model cell line for tumors showing
ERα + phenotype, and our findings provide a compelling
evidence for a comprehensive mechanistic study of
estrogen-mediated epigenetic repression of MT1 cluster
in other breast cancer cell lines representing various
breast cancer subtypes.
Conclusions
Our studies used a sequence-based methylation protocol
(MBD-seq) to identify thousands of breast tumor hyper-
methylated regions, in particular, discovering seven large
contiguous hypermethylated gene clusters from a breast
cancer patient cohort. Importantly, we were able to use
the methylation levels of the cluster to stratify the pa-
tients for overall survival, pointing to the potential prog-
nostic and therapeutic significance for this epigenetic
modification. As these gene clusters were also selected
based on their association with cancer development,
their prognostic potential in determining overall sur-




DNA samples of 77 breast tumors (n = 77) and 10 nor-
mal breast tissues from healthy individuals (n = 10)
(Additional file 1: Table S1) and 38 ICBP breast cancer
cell lines (n = 38) were isolated for subsequent DNA
methylation analysis. The breast tumor samples were
collected from patients at Chile, IRB # 11-11-3239 ap-
proved by UTHSCSA. These tissues were in various
stages of tumor advancement and from patients repre-
senting different ER and PR statuses. The normal sam-
ples were obtained from normal individuals undergoing
reduction mammoplasty (Additional file 3). All tissues
were obtained following approval of the Institutional Re-
view Board committee.
Cell culture
Most of ICBP panel breast cell lines were obtained from
NCI Cancer Biology Program at NCI in November 2008,
except HMEC, MCF7, MDAMB134, BT474, BT20, and
MDA-MB231 were obtained from American Type Culture
Collection (ATCC) (ATCC Breast Cancer Cell Panel,
Manassas, VA, USA). All cell lines have been tested and
authenticated by ATCC and maintained in our labora-
tory for less than 6 months during which all experiments
were conducted. All cell lines were cultured in ATCC rec-
ommended media and conditions. Cell lines MCF7,
MDAMB134, BT474, MDA-MB231, and BT20 were
cultured in DMEM culture medium (Life Technologies,
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vine serum (FBS). For all the treatments with E2 and
DAC, RPMI culture medium without phenol red was used
and supplemented with 10% charcoal stripped-heat inacti-
vated (CSHI) FBS.
MBDCap sequencing analysis
Methylated DNA was eluted by the MethylMiner Meth-
ylated DNA Enrichment Kit (Invitrogen, Carlsbad, CA,
USA) for 77 breast tumors and 10 normal samples ac-
cording to the manufacturer’s instructions. Briefly, 1 μg
of genomic DNA was sonicated and captured by MBD
proteins. The methylated DNA was eluted in 1-M salt
buffer. DNA in each eluted fraction was precipitated by
glycogen, sodium acetate, and ethanol and was resus-
pended in TE buffer. Eluted DNA was used to generate
libraries for sequencing following the standard protocols
from Illumina. MBDCap-seq libraries were sequenced
using the Illumina Genome Analyzer II (Illumina, Inc.,
San Diego, CA, USA) as per manufacturer’s instructions.
Image analysis and base calling were performed with the
standard Illumina pipeline. Sequencing reads were
mapped by ELAND algorithm. Unique reads were up to
36 base pair reads mapped to the human reference gen-
ome (hg18), with up to two mismatches. Reads in satel-
lite regions were excluded due to the large number of
amplifications (Additional file 1: Table S2). The methyla-
tion level was normalized based on the unique read
numbers for each sample by our newly developed linear
method. The 100-bp bin size was used for methylation
level calculation. Within each bin, the methylation level
was quantified by accumulating the read numbers in
which whole or part of the read was located. The follow-





where NRead,t is the normalized read number of the ith
bin and URead,t is the uniquely mapped read number of
the ith bin, is the total uniquely mapped reads number.
‘INT’ function rounds the element (in the parenthesis)
to the nearest integers towards minus infinity, and ‘^’
means the power operator.
Identification of differentially methylated regions
DMRs were identified by comparing the difference of av-
eraged methylation values in a defined region between
tumors vs. normal tissues (Additional file 1: Table S3).
The CGIs in the human genome are based on annota-
tions of UCSC (University of California, Santa Cruz
Genome Browser). The regions could be any length, but
8-kb was used in this study because the majority of CGIsare within 2-kb up- or down-stream of the transcription
start site (5′TSS), and CGI shores are up to 2-kb dis-
tance relative to its CGIs [8]. DMRs were identified by
Student’s t-test to calculate the difference. AR,G refers to
the average methylation level of group G at region R. R
is a given region including m bin size and starting at the
sth bin. MR,G is the methylation levels of each sample of
group G at region R. SA is sample number for group A.
The DMRs (normal controls vs. breast tumors) were de-





;R ¼ bsþ0; bsþ1;…; bsþmð Þ
To further characterize methylation patterns within
each DMR, methylation values from 8-kb window were
divided into three segments equally representing CGI re-
gions and flanking shore regions. For each segment, it
was considered an individual DMR if the P value is
smaller than the thresholds. Within 8-kb windows, the
center is the TSS for each transcript or is in the middle
of its CGI for each intragenic or intergenic region.
Survival analysis
The lifetime of OS was defined as the time between the
first operation or first-line chemotherapy and end of
follow-up or death due to breast cancer. The third quar-
tile (equal 75th percentile) of methylation levels was
used to identify high methylation (HM) and low methy-
lation (LM) of each promoter region. HMs and LMs
were converted to 1 and 0 binary codes to do Kaplan-
Meier survival and Cox proportional hazard model ana-
lysis. We select genes as clusters, who are part of HUGO
gene families and which consist of genes located on the
same chromosome and consecutive geographic region.
The selection criteria for combination of family genes
were that they were grouped by hazard ratio higher or
lower than one with log-rank test P < 0.3 calculated for
individual genes in the family (here, we assume that in-
cluding borderline significant genes will collaboratively
contribute towards significant association with disease
outcome). In a combination of the same family genes,
the receiver operating characteristic (ROC) curve was
used to select an optimal cutoff value for the numerous
HM of promoter regions. Bootstrapping was performed
200 times, and ‘best’ methods were used to classify dead
and alive patients by pROC package of R (version 2.13).
E2 and DAC treatment
Cell lines were incubated in charcoal stripped media for
24 h and then treated with DAC (1 μM) for 72 h. The cells
were further treated with E2 (70 nM) for 36 h with and
without DAC treatment. RNA was isolated from harvested
cells, which were then harvested and subjected to real-
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PCR primers are outlined in Additional file 1: Table S4,
and conditions are described previously [42]. Relative
expression was determined by the formula 2−ΔΔCt.
ERE luciferase assay
MCF7 cells were transfected in triplicate with ERE and
Renilla vectors, kindly supplied by Dr. Rong Li, Depart-
ment of Molecular Medicine, University of Texas Health
Science Center (50:1 to make total DNA of 110 ng/well)
for 24 h. Cells were incubated with charcoal strip media
for 24 h and then treated with E2 for 24 h. The ERE and
Renilla activity was calculated with Dual-Glo Luciferase
Assay Kit (Promega, Madison, WI, USA).
Cell invasion assay and proliferation assays
Specific siRNA was used to knockdown MT1F and
MT1M expression (Thermo Scientific). MCF7 (approxi-
mately 50,000 cells) was transfected with MT1F and
MT1M siRNA seeded onto the top insert (layered with
Matrigel) of an invasion chamber (BD Biosciences,
Franklin Lakes, NJ, USA). The invasion chambers were
then incubated at 37°C in 5% CO2 for 20 h. Cells that
did not invade through the Matrigel (on the upper
surface of the insert membrane) were mechanically re-
moved with cotton tip applications and several washes
with PBS. Invaded cells on the bottom of the coated
membranes were visualized using a fluorescence micro-
scope with a × 20 objective after incubation with Hoechst
stain (Life Technologies). Images were obtained from
four standardized non-overlapping fields. Invaded cells
were counted using the Image J software (http://rsbweb.
nih.gov/ij/). Invasion assays were done in triplicate; images
of four fields per well (covering about 85% of the well)
were taken for counting invaded cells. Cellular prolifer-
ation was assayed using CellTiter-Glo® Luminescence
Kit (Promega, Madison, WI, USA) according to the
manufacturer’s directions as described earlier [43].
Bioinformatics and statistical analysis
We considered statistical significance as P < 0.05 for all
analyses unless explicitly stated. Student’s t-test was
used to compare RT-qPCR, and invasion assay results
in different treatment and control groups. Statistical
significance was assigned as * if P < 0.05, ** if P < 0.01,
and *** if P < 0.001.
GC content and phastCons score: For each gene, we
retrieved a genomic region with a length of 8-kb DNA
sequence spanning from 4-kb upstream to 4-kb down-
stream around 5′TSS. The regions were then divided
into 160 bins with a bin size of 50 bp. The GC content
is calculated for each bin as the number of G + C in that
particular bin divided by the bin size of 50. The phast-
Cons score is calculated for each bin using the valuesfrom UCSC genome browser (http://hgdownload.soe.ucsc.
edu/goldenPath/hg18/phastCons44way/). The phastCons
score represents conservation information among 45
species. For each gene cluster, we simply calculated the
mean and standard deviation values from all member
genes in the cluster for all 160 bins. We also used the
whole RefSeq gene set as a background control.
In silico gene expression correlation: The clinical infor-
mation and gene expression values for the breast tumors
and normal tissues were downloaded from the TCGA
website (http://cancergenome.nih.gov/). A total of 106
normal tissue samples and 988 primary tumor samples
with mRNA expression information are currently avail-
able for the correlation analysis. Of 988 tumor samples,
207 tumor samples are ERα−, 704 tumor samples are
ERα+, and 77 tumor samples are classified as unknown
due to missing clinical information. We then used the
gene expression values for our seven gene clusters and
created an expression matrix to examine their expression
pattern. We applied a z-score normalization method on
each individual gene on their log-transformed RPKM
values across the sample set. In addition, we have calcu-
lated the log2 fold change values for normal group vs.
tumor group and ERα − group vs. ERα−, respectively. A
visualization map for the matrix was constructed by Py-
thon library package.
In silico correlation between expression and DNA
methylation: RNA-seq and DNA methylation values
were retrieved from TCGA using CGDSR library in R.
The patient samples showing values for both RNA-seq
and DNA methylation for each patient were retained.
Scatterplots showing correlation between RNA-seq and
DNA methylation were created after excluding the out-
liers falling in top and bottom 5 quartile of the data.
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